BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 31787568)

  • 21. The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study.
    Özkocaman V; Özkalemkaş F; Seyhan S; Ener B; Ursavaş A; Ersal T; Kazak E; Demirdöğen E; Mıstık R; Akalın H
    Turk J Haematol; 2018 Nov; 35(4):277-282. PubMed ID: 30047484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
    Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study.
    Chen X; Wang J; Wang S; Jin J; Li J; Gao S; Li J; Li J; Liu Q; Hu Y; Lin D; Sun Z; Yang J; Hu J; Wu X; Huang X; Shao Z; Deng Q; Wang C; Liu L; Chen H; Wang J; Wei X; Shen J; Zhang X; Wu D
    Medicine (Baltimore); 2021 Jul; 100(30):e26772. PubMed ID: 34397725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China.
    Xu XH; Zhang L; Cao XX; Li J; Zhang W; Zhu TN; Cai HC; Chen M; Han X; Yang C; Han B; Zhang Y; Zhuang JL; Zhou DB; Duan MH
    J Infect Chemother; 2017 Jun; 23(6):360-367. PubMed ID: 28341518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
    Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
    Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
    Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
    N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
    Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
    Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
    Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of a multidisciplinary team for preventing hospital-acquired invasive aspergillosis: five years' experience].
    Etancelin P; Silly S; Merle V; Bonmarchand G; Richard JC; Vannier JP; Nouvellon M
    Pathol Biol (Paris); 2009 Feb; 57(1):71-5. PubMed ID: 19157722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
    Pungprasert T; Dhirachaikulpanich D; Phutthasakda W; Tantai N; Maneeon S; Nganthavee V; Atipas K; Tanpong S; Krithin S; Tanglitanon S; Jutidamrongphan W; Chayakulkeeree M; Srinonprasert V; Phikulsod P
    J Hosp Infect; 2024 Mar; 145():118-128. PubMed ID: 38219835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.
    Pagano L; Caira M; Candoni A; Aversa F; Castagnola C; Caramatti C; Cattaneo C; Delia M; De Paolis MR; Di Blasi R; Di Caprio L; Fanci R; Garzia M; Martino B; Melillo L; Mitra ME; Nadali G; Nosari A; Picardi M; Potenza L; Salutari P; Trecarichi EM; Tumbarello M; Verga L; Vianelli N; Busca A;
    Clin Infect Dis; 2012 Dec; 55(11):1515-21. PubMed ID: 22955439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
    Lerolle N; Raffoux E; Socie G; Touratier S; Sauvageon H; Porcher R; Bretagne S; Bergeron A; Azoulay E; Molina JM; Lafaurie M
    Clin Microbiol Infect; 2014 Nov; 20(11):O952-9. PubMed ID: 24861577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey.
    Del Principe MI; Dragonetti G; Conti A; Verga L; Ballanti S; Fanci R; Candoni A; Marchesi F; Cattaneo C; Lessi F; Fracchiolla N; Spolzino A; Prezioso L; Delia M; Potenza L; Decembrino N; Castagnola C; Nadali G; Picardi M; Zama D; Orciulo E; Veggia B; Garzia M; Dargenio M; Melillo L; Manetta S; Russo D; Mancini V; Piedimonte M; Tisi MC; Toschi N; Busca A; Pagano L; ;
    Mycoses; 2022 Feb; 65(2):171-177. PubMed ID: 34695256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
    Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
    Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
    Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
    Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
    Ullmann AJ; Aguado JM; Arikan-Akdagli S; Denning DW; Groll AH; Lagrou K; Lass-Flörl C; Lewis RE; Munoz P; Verweij PE; Warris A; Ader F; Akova M; Arendrup MC; Barnes RA; Beigelman-Aubry C; Blot S; Bouza E; Brüggemann RJM; Buchheidt D; Cadranel J; Castagnola E; Chakrabarti A; Cuenca-Estrella M; Dimopoulos G; Fortun J; Gangneux JP; Garbino J; Heinz WJ; Herbrecht R; Heussel CP; Kibbler CC; Klimko N; Kullberg BJ; Lange C; Lehrnbecher T; Löffler J; Lortholary O; Maertens J; Marchetti O; Meis JF; Pagano L; Ribaud P; Richardson M; Roilides E; Ruhnke M; Sanguinetti M; Sheppard DC; Sinkó J; Skiada A; Vehreschild MJGT; Viscoli C; Cornely OA
    Clin Microbiol Infect; 2018 May; 24 Suppl 1():e1-e38. PubMed ID: 29544767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
    Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive Aspergillosis in Patients with Acute Leukemia: Comparison Between Acute Myeloid and Acute Lymphoid Leukemia.
    Colombo AL; Bergamasco MD; Nouér SA; Oliveira E Castro PT; Pasqualotto AC; de Queiroz-Telles F; Abdala E; Ramos JF; Falci DR; Nucci M
    Mycopathologia; 2023 Apr; 188(1-2):1-8. PubMed ID: 36316599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.